1E Therapeutics
Elhanan Pinner is a seasoned scientist with extensive experience in drug discovery and pre-clinical development. Currently serving as a Senior Scientist at 1E Therapeutics since March 2022, Elhanan previously held the position of Research Scientist at the Weizmann Institute of Science from January 2018 to March 2022. Prior to that, Elhanan managed CNS projects at Neurim Pharmaceuticals Ltd from February 2005 to 2017, focusing on Alzheimer's disease, ALS, and Parkinson's disease. Elhanan also directed cardiovascular projects at QBI, working on drug target validation for congestive heart failure in collaboration with a major pharmaceutical company from 2002 to 2005. Earlier in the career, Elhanan led a team at Compugen from 1999 to 2002, specializing in the validation and characterization of genes and proteins identified through in silico methods. Elhanan Pinner holds a PhD in molecular biology from The Hebrew University of Jerusalem and furthered education at McGill University.